脾体积作为奥沙利铂为基础的化疗后血小板减少症和肝功能障碍的预测生物标志物。
Spleen Volume as a Predictive Biomarker for Thrombocytopenia and Liver Dysfunction After Oxaliplatin-based Chemotherapy.
机构信息
Department of General and Digestive Surgery, Kanazawa Medical University Hospital, Ishikawa, Japan.
Department of General and Digestive Surgery, Kanazawa Medical University Hospital, Ishikawa, Japan
出版信息
Anticancer Res. 2020 Jun;40(6):3361-3370. doi: 10.21873/anticanres.14319.
BACKGROUND/AIM: We evaluated whether splenic volume (SV) predicts sinusoidal obstruction syndrome (SOS) in colorectal cancer (CRC) patients receiving capecitabine plus oxaliplatin (CapeOX) therapy.
PATIENTS AND METHODS
In this retrospective study, we measured SV in 41 patients receiving adjuvant CapeOX for CRC at five different time points. We compared the clinical data of the 18 patients who experienced ≥30% increases in SV immediately after vs. before CapeOX (group A) with data for the remaining 23 patients (group B).
RESULTS
Platelet numbers decreased and the levels of hepatobiliary enzymes increased significantly 1 year after CapeOX compared with before CapeOX in group A. However, in group B, significantly decreased platelet numbers and significantly increased aspartate transaminase levels were confirmed only immediately after CapeOX, with no significant subsequent changes.
CONCLUSION
SV was significantly associated with thrombocytopenia and liver dysfunction in CRC patients, and predicted SOS.
背景/目的：我们评估了在接受卡培他滨联合奥沙利铂（CapeOX）治疗的结直肠癌（CRC）患者中，脾脏体积（SV）是否可预测窦状隙阻塞综合征（SOS）。
患者与方法
在这项回顾性研究中，我们在 41 例接受 CRC 辅助 CapeOX 治疗的患者中，在五个不同时间点测量了 SV。我们比较了在 CapeOX 后 SV 立即增加≥30%的 18 例患者（A 组）与其余 23 例患者（B 组）的临床数据。
结果
与 CapeOX 前相比，A 组在 CapeOX 后 1 年血小板数量减少，肝胆酶水平升高显著。然而，在 B 组，仅在 CapeOX 后即刻确认血小板数量显著减少和天冬氨酸转氨酶水平显著升高，随后无明显变化。
结论
SV 与 CRC 患者的血小板减少和肝功能障碍显著相关，并可预测 SOS。
Zotero 插件